Efficacy of different cooling technologies for therapeutic temperature management: A prospective intervention study

• Published in: Resuscitation
• Main Authors: Sonder, Petra, Janssens, Gladys N., Beishuizen, Albertus, Henry, Connie L., Rittenberger, Jon C., Callaway, Clifton W., Dezfulian, Cameron, Polderman, Kees H.
• Format: Article in Journal/Newspaper
• Language: English
• Published: 2018
• Subjects: Arctic
• Online Access: https://research.vumc.nl/en/publications/746d8e43-a354-4311-88e1-8bb24808a6f4; https://doi.org/10.1016/j.resuscitation.2017.12.026; https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85039752497&origin=inward; https://www.ncbi.nlm.nih.gov/pubmed/29288014

Background Mild therapeutic hypothermia (32–36 °C) is associated with improved outcomes in patients with brain injury after cardiac arrest (CA). Various devices are available to induce and maintain hypothermia, but few studies have compared the performance of these devices. We performed a prospective study to compare four frequently used cooling systems in inducing and maintaining hypothermia followed by controlled rewarming. Methods We performed a prospective multi-centered study in ten ICU's in three hospitals within the UPMC health system. Four different cooling technologies (seven cooling methods in total) were studied: two external water-circulating cooling blankets (Meditherm® and Blanketrol®), gel-coated adhesive cooling pads (Arctic Sun®), and endovascular cooling catheters with balloons circulating ice-cold saline (Thermogard®). For the latter system we studied three different types of catheter with two, three or four water-circulating balloons, respectively. In contrast to previous studies, we not only studied the cooling rate (i.e., time to target temperature) in the induction phase, but also the percentage of the time during the maintenance phase that temperature was on target ±0.5 °C, and the efficacy of devices to control rewarming. We believe that these are more important indicators of device performance than induction speed alone. Results 129 consecutive patients admitted after CA and treated with hypothermia were screened, and 120 were enrolled in the study. Two researchers dedicated fulltime to this study monitored TH treatment in all patients, including antishivering measures, additional cooling measures used (e.g. icepacks and cold fluid infusion), and all other issues related to temperature management. Baseline characteristics were similar for all groups. Cooling rates were 2.06 ± 1.12 °C/h for endovascular cooling, 1.49 ± 0.82 for Arctic sun, 0.61 ± 0.36 for Meditherm and 1.22 ± 1.12 for Blanketrol. Time within target range ±0.5 °C was 97.3 ± 6.0% for Thermogard, 81.8 ± 25.2% for Arctic ...